TLR2 and neoplasm: Wu et al. found that lipo-OVA (Ovalbumin fused with the TLR2 agonist, the lipid part of the bacteria) showed a strong anti-tumor effect by activating BMDCs maturation, promoting cross-presentation of tumor antigen, inducing CTL responses, increasing the numbers of CD8+ T cells (Wu et al., 2016).